FiberSense received CE marking for its optical CGM system with up to 28-day wear, while LifeScan partnered with i-SENS to launch the OneTouch Vita CGM and appointed a new CEO. Senseonics' year-long Eversense 365 implantable CGM is also detailed.
InsideTracker's peer-reviewed PLOS Digital Health study of 20,000 users found sustained improvements across 39 blood biomarkers, including LDL, HbA1c, glucose, vitamin D, hsCRP and testosterone, linked to use of its personalized platform.
A securities class action alleges Corcept misled investors about the regulatory prospects for relacorilant. The suit cites an FDA Complete Response Letter, a 50.4% stock drop, and an April 21, 2026 lead plaintiff deadline.
The U.S. Court of Appeals for the Federal Circuit ruled that Teva Pharmaceuticals did not infringe Corcept Therapeutics' patents for methods of safely co-administering Korlym with CYP3A4 inhibitors, affirming a 2023 district court verdict.
